Introduction {#s1}
============

Coronary heart disease is the leading cause of mortality worldwide, causing 7.4 million deaths in 2015. To treat cardiac ischaemia, primary percutaneous coronary intervention is used to re-open the culprit coronary artery, but this does not guarantee reperfusion of the downstream capillaries supplying the myocardium ([@bib25]; [@bib22]). A lack of capillary reperfusion - 'no-reflow' - affects up to 50% of patients ([@bib38]), and predicts a raised prevalence of deleterious complications including congestive heart failure, malignant arrhythmias and cardiac death ([@bib38]; [@bib56]; [@bib34]; [@bib41]; [@bib23]). No-reflow has been attributed to swollen endothelial cells and/or cardiomyocytes compressing the lumen of capillaries ([@bib23]), or to leukocytes adhering to and plugging capillaries ([@bib12]). However, although depleting blood of granulocytes reduces no-reflow ([@bib11]), leukocyte adhesion to capillaries in reperfused hearts is modest compared to the adhesion seen in post-capillary venules ([@bib15]). No treatment exists for coronary no-reflow after decades of investigation, even though it predicts a worse outcome after myocardial ischaemia ([@bib38]; [@bib56]; [@bib34]; [@bib41]; [@bib23]). We therefore sought an alternative explanation for coronary capillary narrowing, which might trap leukocytes or red blood cells physically, based on recent advances in our understanding of the similar no-reflow phenomenon which occurs after brain ischaemia ([@bib40]).

In the brain and retina, blood flow is partly regulated by contractile pericytes located on capillaries ([@bib19]), which respond to vasoactive messengers released from active neurons and astrocytes by altering their tone, thus altering capillary diameter and blood flow ([@bib43]; [@bib45]; [@bib16]; [@bib4]; [@bib10]; [@bib21]). Furthermore, ischaemia, spinal cord injury and epilepsy lead to a contraction of pericytes, causing constriction of capillaries ([@bib17]; [@bib43]; [@bib57]; [@bib16]; [@bib29]; [@bib27]), and for ischaemia this is followed by the pericytes dying in rigor ([@bib16]) which hinders subsequent capillary dilation. Pericytes also exist in the heart ([@bib55]), where they are the second most numerous cell type after endothelial cells ([@bib37]). They are poorly understood (only 1 in 5000 cardiac papers in PubMed mentions pericytes): it is debated whether they are contractile ([@bib55]; [@bib20]) and attention has focused on other possible functions for them including angiogenesis, immune defence, haemostasis and cardiac regeneration ([@bib36]; [@bib5]). Here we show that ischaemia-induced constriction of coronary capillaries by pericytes contributes to no-reflow after cardiac ischaemia.

Results {#s2}
=======

Pericytes associate with capillaries and sympathetic axons, and express actin {#s2-1}
-----------------------------------------------------------------------------

The left ventricular coronary capillary bed comprises an array of parallel capillaries linked by occasional connector capillaries running roughly orthogonal to the main direction of flow ([Figure 1A](#fig1){ref-type="fig"}). Labelling capillaries with FITC- or Alexa647-isolectin B~4~, and pericytes in rat with antibody to NG2 ([Figure 1A](#fig1){ref-type="fig"}) or PDGFRβ ([Figure 1C](#fig1){ref-type="fig"}), or in mouse with transgenic expression of DsRed under the NG2 promoter ([Figure 1C](#fig1){ref-type="fig"}), showed that the great majority of coronary capillaries were contacted by pericytes. Pericytes differ from vascular smooth muscle cells in that their somata are spatially separated along the capillary, located either with a bump-on-a-log appearance on the straight parts of capillaries, or at the branch points of capillaries ([@bib1]). More of the parallel capillaries than of the connector capillaries linking adjacent parallel capillaries received pericyte contacts (92% vs 66%, p=2.2×10^−5^, [Figure 1B](#fig1){ref-type="fig"}).The great majority of pericytes labelled for both NG2 and PRGFRβ ([Figure 1D](#fig1){ref-type="fig"}), although a small fraction (6.4 ± 0.2%) of PDGFRβ-expressing pericytes did not express NG2 (p=2.3×10^−7^). Overall there is one pericyte every \~60 μm along rat coronary capillaries, independent of location in the left ventricle ([Figure 1F](#fig1){ref-type="fig"}) although there is variability around this mean distance ([Figure 1A,G](#fig1){ref-type="fig"}).

![Cardiac pericyte morphology is appropriate for regulating capillary diameter.\
(**A**) Coronary capillaries in rat left ventricle (dashed arrows in left panel show longitudinal capillaries, solid arrows show connector capillaries) labelled for basement membrane (FITC-isolectin B~4~) and for pericytes (example somata labelled with arrows in right panel) with antibody to the proteoglycan NG2. (**B**) A larger percentage of parallel capillaries (in rat,) receive pericyte contacts (\<1 μm away) than do connector capillaries running between the parallel capillaries. (**C**) Mouse pericytes labelled with antibody to PDGFRβ (example somata labelled with arrows) and with NG2-DsRed. (**D**) Percentage of 2874 NG2-expressing pericytes (left) that also express PDGFRβ and of 3047 PDGFRβ−expressing pericytes (right) that also expressed NG2 (averaged over 36 confocal stacks each, from 4 mice, 2--9 months old) in the left ventricle of NG2-dsRed mice. (**E**) Pericyte in NG2-DsRed mouse showing soma (white arrow) and circumferential and longitudinal processes (yellow arrows). (**F**) The mean rat pericyte inter-soma distance is similar in the lateral wall of the left ventricle (LLV), the septal wall of the left ventricle (SLV), and anterior and posterior walls of the left ventricle (APLV). (**G**) Mouse pericyte circumferential processes can extend over much of the capillary surface between pericyte somata. (**H**) Labelling of tyrosine hydroxylase (blue) shows a close association of sympathetic axons (white arrows) with rat pericytes (cyan arrows). (**I**) At higher magnification, tyrosine hydroxylase labelled axon varicosities (putative transmitter release sites, cyan) can be seen apposed to pericyte somata and processes. (**J**) Both capillaries and pericytes (including soma and processes) frequently have sympathetic axon varicosities within 1 μm (in rat). (**K--M**) Examples of pericytes labelled with Alexa647-isolectin B~4~ (red) that also labelled (green) for α-SMA (**K**), β-actin (**L**) or γ1-actin (**M**). White arrows indicate somata; yellow arrows indicate actin-labelled processes. (**N**) Percentage of pericytes expressing the 3 actin isoforms in three hearts. Data are mean ± s.e.m. Numbers on bars are of capillaries (panels **B**, **J**), images (**D**), intersoma distances (**F**) or pericytes (**J, N**).](elife-29280-fig1){#fig1}

Pericytes extend circumferential processes ([Figure 1E,G](#fig1){ref-type="fig"}), the contraction of which would directly alter capillary diameter. Contraction of their longitudinal processes could alter the stiffness of the capillary wall and regulate its deformability by passing blood cells. Either of these mechanisms could regulate capillary blood flow. Indeed, varying degrees of contraction of these pericytes is a plausible explanation for the large variance of capillary blood transit time in the coronary circulation ([@bib46]), which has a significant effect on oxygen extraction by the myocardium ([@bib42]). We found that approximately 50% of pericytes are located close to varicosities of tyrosine hydroxylase expressing sympathetic axons ([Figure 1H--J](#fig1){ref-type="fig"}), suggesting the possibility of noradrenergic regulation of pericyte tone.

Pericytes are conventionally assumed to constrict capillaries using α-smooth muscle actin (α-SMA: [@bib20]; [@bib52]), but variability in the labelling observed for α-SMA and data showing expression of other actin isoforms in pericytes has led to a suggestion, for CNS pericytes, that γ-actin might instead be the relevant actin isoform ([@bib7]; [@bib14]). We therefore examined antibody labelling for α-SMA, β-actin and γ-actin ([Figure 1K--M](#fig1){ref-type="fig"}). α-SMA labelling occurred in 36.4 ± 6.7% of 57 pericytes ([Figure 1N](#fig1){ref-type="fig"}), and was rarer than labelling for β-actin (62.3 ± 2.8% of 30 pericytes) or γ-actin (76.0 ± 3.4% of 47 pericytes). α-SMA-expressing pericytes were most commonly observed in capillaries closer to the arteriole end of the capillary bed, while β- and γ-actin were seen in pericytes across the capillary bed.

No-reflow occurs after coronary ischaemia {#s2-2}
-----------------------------------------

To examine the possible role of contraction of pericytes in ischaemic pathology, we occluded the left anterior descending (LAD) coronary artery for 45 mins, depriving the anterior wall of the left ventricle and part of the right ventricle of blood (see Materials and methods). We then removed the occlusion to allow reperfusion for 15 mins, so that any rapidly reversible obstruction of blood vessels produced by ischaemia would be removed, leaving only long-lasting vessel obstruction contributing to the no-reflow phenomenon. At the end of this period FITC-albumin in gelatin was perfused to visualise vessels where flow was present, and the tissue was sectioned and labelled with isolectin B~4~ conjugated to Alexa Fluor 647 to visualise non-perfused vessels. In control (sham LAD artery occlusion) hearts, perfusion was visible throughout the whole cross section of the left and right ventricles ([Figure 2A](#fig2){ref-type="fig"}). The perfused blood volume per unit area (assessed from the mean FITC-albumin intensity in regions of interest) was fairly uniform around the left ventricle ([Figure 2C](#fig2){ref-type="fig"}), although somewhat higher in the posterior wall (regions of interest (ROIs) 4--6 of [Figure 2C](#fig2){ref-type="fig"}). In contrast, occlusion and reperfusion of the LAD artery resulted in microvascular perfusion being greatly reduced after the period of ischaemia in half of the left and right ventricles ([Figure 2B](#fig2){ref-type="fig"}), as quantified for the left ventricle in [Figure 2C](#fig2){ref-type="fig"} (reduced by 49% compared to sham-operated animals in ROIs 7--10: p=0.0004).

![Ischaemia and reperfusion lead to no-reflow mediated by capillary block.\
(**A, B**) Low power view of sham-operated heart (**A**) and a heart after LAD coronary artery occlusion and reperfusion (**B**), with perfusion volume assessed as intensity of FITC-albumin (green). In (**B**) vessels are also labelled with isolectin B~4~ - Alexa Fluor 647 (purple) to define location of unperfused tissue. Regions of interest (ROIs) for analysing the intensity of FITC-albumin fluorescence are shown in yellow. (**C**) Perfused volume (assessed from mean FITC-albumin intensity), in ROIs indexed with numbers starting at the interventricular septum and proceeding clockwise around the left ventricle (as seen from above), for five sham-operated hearts (control), six hearts made ischaemic and reperfused (ischaemia), and eight hearts made ischaemic and exposed to adenosine starting 5 min before reperfusion (isch + ado). (**D**) Percentage of capillaries blocked in the anterior wall of the left ventricle for the three experimental conditions (numbers on bars are of 'capillaries examined, image stacks examined'). Data are mean ± s.e.m. P values are corrected for multiple comparisons.](elife-29280-fig2){#fig2}

Pericytes constrict capillaries after ischaemia {#s2-3}
-----------------------------------------------

Higher magnification images revealed that in control hearts only 3% of capillaries were blocked (i.e. not perfused by FITC-albumin) in the left ventricle. In contrast, LAD artery occlusion and reperfusion increased this to 40% in the affected area ([Figure 2D](#fig2){ref-type="fig"}). Some capillaries were completely perfused and some were completely unperfused throughout the imaged area, while some capillaries showed an abrupt cessation of perfusion ([Figure 3A--F](#fig3){ref-type="fig"}), with a profound decrease of FITC-albumin intensity that occurred over a few microns ([Figure 3G](#fig3){ref-type="fig"}). Since leukocytes are both larger and less deformable than erythrocytes ([@bib49]; [@bib9]; [@bib24]; [@bib8]), it seemed more likely that leukocytes rather than red blood cells would get stuck at capillary regions of reduced diameter. Surprisingly, labelling with antibody to neutrophil elastase or ICAM-1 revealed no leukocytes lodged at 46 blockage sites examined (although, as a positive control, they were seen outside vessels, [Figure 3K](#fig3){ref-type="fig"}, usually post-capillary venules). Similarly, labelling for the erythrocyte protein glycophorin A revealed red blood cells ([Figure 3L](#fig3){ref-type="fig"}) associated with only a small percentage of blockage sites (18% of 44 blockages), and even where red blood cells were trapped at capillary constrictions it did not always lead to a block of blood flow (as shown by FITC-albumin passing the red blood cells). However, examining NG2 labelling at the sites of block revealed that many blockages occurred close to pericytes, in some cases with pericyte processes appearing to visibly constrict the capillary at the block location ([Figure 3A--C](#fig3){ref-type="fig"}).

![No-reflow reflects blockage by pericyte constriction.\
(**A**) Image of perfused and non-perfused capillaries in post-ischaemic left ventricle. Isolectin B~4~ labelling (white) defines positions of all vessels, while FITC-albumin labelling (green) shows vessels that are perfused. Bottom left capillary is completely non-perfused; top green capillary is fully perfused; lower green capillary is blocked halfway across the image. (**B, C**): NG2-labelling of pericytes (**B**) and merge (**C**) of the images (**A**) and (**B**) show pericyte processes constricting vessel at block site. (**D--F**) Another example set of images as in (**A--C**), showing two capillaries blocked near pericyte somata. (**G**) Normalised intensity of (background-subtracted) FITC-albumin (green) labelling along the centre of the capillary lumen across 20 block sites. (**H**) Cumulative probability distribution for the distance from capillary blockage sites to the nearest pericyte soma (black) and for the position expected (see [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}) if blocks occurred at positions independent of pericyte locations (significantly different, p=3.9×10^−5^). Comparing the experimental distribution with a theoretical distribution increasing linearly to one at a distance of 30 μm (see Image Analysis in Materials and methods) also showed a significant difference (p=7.6×10^−8^). (**I**) Ratio of capillary diameter at pericyte somata to the diameter at positions \~ 10 μm upstream after ischaemia, after ischaemia with adenosine (ado), and for sham-operated hearts (Con). (**J**) Diameter at pericyte somata after ischaemia, after ischaemia with adenosine, and for sham-operated hearts (Con) (all pericyte locations were measured, not just those associated with capillary blockages, for which the mean diameter after ischaemia was smaller: 3.19 ± 0.24 μm, n = 30). (**K**) Capillary blockage in an area of the heart with a neutrophil (labelled for neutrophil elastase, NE, bottom left) present outside the capillaries. (**L**) Pericyte (labelled with isolectin B~4~) near a blockage constricting a vessel with two red blood cells (RBCs, labelled for glycophorin A) trapped in the constriction. (**M**) Blockage-associated pericyte (labelled for NG2) that also labels for α-SMA. Numbers on bars are of pericytes. Data are mean ± s.e.m. P values in I-J are from Mann-Whitney tests and are corrected for multiple comparisons.](elife-29280-fig3){#fig3}

To assess rigorously whether block occurred disproportionately close to pericytes, we measured the distance of 42 blockages to the nearest pericyte soma. The cumulative probability distribution of this distance showed the median distance to be 3.6 μm ([Figure 3H](#fig3){ref-type="fig"}). In contrast, when we used the same 42 images to calculate what the average distance of a blockage to the nearest pericyte soma would be if blockages were randomly placed on the blocked capillaries in the images (see [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}), the cumulative probability distribution for that distance predicted a median distance of 11.6 μm ([Figure 3H](#fig3){ref-type="fig"}; significantly different, p=3.9×10^−5^). Thus, ischaemia-evoked capillary block occurs disproportionately close to pericytes.

To verify that pericytes constrict coronary capillaries in ischaemia, we measured the diameter of the FITC-albumin labelled lumen at pericyte somata, and at a distance 10 μm upstream of the soma (since most circumferential processes of pericytes are located less than 10 μm from the soma). In sham-operated animals, the ratio of the diameter at the soma to that upstream was 1.058 ± 0.015 (n = 20, significantly greater than one, p=0.001, [Figure 3I](#fig3){ref-type="fig"}), consistent with the presence of the pericyte soma inducing growth of the capillary lumen, as found previously for brain pericytes ([@bib16]). In contrast, for capillaries after ischaemia, this ratio was 0.822 ± 0.022 (n = 60, significantly less, p=1.4×10^−8^, [Figure 3I](#fig3){ref-type="fig"}), implying that constriction occurs near the pericyte soma. The absolute diameter measured at pericyte somata was reduced by 37% after ischaemia and reperfusion (compared to sham-operated hearts, p=3.1×10^−6^, [Figure 3J](#fig3){ref-type="fig"}).

Pericytes near blockage sites were tested for labelling of the different actin isoforms mentioned above. All 4 such pericytes tested for α-SMA labelling exhibited labelling ([Figure 3M](#fig3){ref-type="fig"}), as did 5 out of 6 tested for β-actin, and all 6 tested for γ-actin. Since only a small fraction of pericytes may need to constrict a capillary to abolish its blood flow, further work is needed to determine which is the main actin isoform responsible for the ischaemia-evoked contraction of pericyte processes and reduction of blood flow.

Since cardiac catecholamine transporters reverse and release noradrenaline and adrenaline in ischaemia ([@bib26]), and noradrenaline acts on pericytes in the brain to constrict capillaries ([@bib43]), we assessed whether blocking adrenergic α~1~ receptors reduced the percentage of capillaries blocked after ischaemia. We found no effect of injecting terazosin (0.5 mg/kg i.v., 5 mins before occluding the LAD artery, which produced a 20--33 mm Hg decrease of blood pressure), with 48.8 ± 3.7% of capillaries blocked in the presence of terazosin (in 13 images covering 383 capillaries in 2 hearts; not significantly different from the 44.7 ± 4.9% seen for 14 images covering 366 capillaries in 2 hearts in interleaved experiments without terazosin, p=0.52). We therefore sought an alternative pharmacological approach to reducing no-reflow after ischaemia.

Adenosine reduces pericyte constriction and no-reflow {#s2-4}
-----------------------------------------------------

Adenosine has been suggested to reduce no-reflow after cardiac ischaemia, although its clinical utility remains uncertain ([@bib3]; [@bib53]). Adenosine is also thought to relax pericytes ([@bib31]; [@bib28]; [@bib13]). We infused adenosine intravenously (at 0.5 mg/kg/min, similar to doses used previously to treat no-reflow in humans and other animals: see Materials and methods), from 5 mins before the end of ischaemia until 10 mins of reperfusion had occurred (see Materials and methods), and examined its effect on capillary block. Adenosine significantly reduced (p=0.03) the decrease of coronary perfusion seen after ischaemia ([Figure 2C](#fig2){ref-type="fig"}, the mean value in ROIs 7--10 in [Figure 2C](#fig2){ref-type="fig"} was increased by 57% compared to ischaemia without adenosine, and was not significantly different from that in control conditions, p=0.77). This increase of flow could reflect adenosine acting both on arteriolar smooth muscle and on pericytes. However, adenosine also reduced by one quarter the percentage of capillaries that were blocked after reperfusion, from \~40% to \~30% (p=0.007, [Figure 2D](#fig2){ref-type="fig"}). An analysis like that in [Figure 3H](#fig3){ref-type="fig"} showed that the remaining sites of block were still significantly associated with pericyte locations (p=0.001). Since the capillary blockages induced by ischaemia in the absence of adenosine are disproportionately associated with pericytes, and since the adenosine was only applied around the period of reperfusion, these data suggest that, at least in part, adenosine reduces no-reflow by reversing the constriction of pericytes that ischaemia induces. To test this hypothesis, we compared the diameter of capillaries at pericyte somata with the diameter 10 μm upstream of the soma and found that adenosine significantly (p=0.0045) reduced the constriction evoked by ischaemia at pericyte somata ([Figure 3I](#fig3){ref-type="fig"}), implying a specific effect on pericytes (rather than a general capillary dilation produced by upstream arteriole dilation). The absolute capillary diameter at pericyte somata after ischaemia was increased by 21% using adenosine (p=0.025, [Figure 3J](#fig3){ref-type="fig"}). Thus, adenosine decreases no-reflow by relaxing pericytes.

Discussion {#s3}
==========

Our data suggest a novel therapeutic target for reducing no-reflow after cardiac ischaemia: during ischaemia pericytes constrict and block coronary capillaries, probably because pericyte \[Ca^2+^\]~i~ rises when ion pumping stops in ischaemia. Three lines of evidence support this idea. First, sites of capillary blockage are disproportionately associated with pericyte locations ([Figure 3H](#fig3){ref-type="fig"}). Second, after ischaemia the diameter of capillaries is reduced specifically at pericyte somata ([Figure 3I,J](#fig3){ref-type="fig"}). Third, adenosine, which is thought to relax pericytes, increases the post-ischaemic diameter of capillaries at pericyte locations ([Figure 3I,J](#fig3){ref-type="fig"}) and reduces the percentage of capillaries that remain blocked when the upstream artery is reperfused after ischaemia ([Figure 2D](#fig2){ref-type="fig"}). Prevention or reduction of pericyte constriction should therefore reduce the flow impairment that causes significant functional impairment after removal of a thrombus in a coronary artery.

The most plausible explanation of our data is that, like pericytes in the CNS ([@bib43]; [@bib16]), cardiac pericytes extend actomyosin-containing processes around coronary capillaries that, when their \[Ca^2+^\]~i~ rises and contraction is activated, reduce capillary diameter (see Supplementary Movie 1 of [@bib43]). Indeed, cardiac pericytes express both actin and myosin ([@bib20]; [@bib52]). It is likely that pericytes do not need to completely constrict a capillary in order to stop blood flow in that vessel, because a reduction in diameter (like the 37% in [Figure 3J](#fig3){ref-type="fig"}) may prevent the passage of leukocytes ([@bib12]) or red blood cells ([Figure 3L](#fig3){ref-type="fig"}), causing a blockage that prevents the passage of both plasma and cells. The fact that we observed few cells in the capillary lumen at blockages may result from their displacement during the perfusion with FITC-albumin in gelatin, or may alternatively reflect capillary block occurring when constriction brings together the layers of glycocalyx ([@bib50]) on opposite sides of the capillary.

It is uncertain whether, over a long period, cardiac pericyte death in rigor occurs and contributes to generating a long lasting reduction of blood flow, as suggested for the CNS ([@bib16]). Clearly not all pericytes die during the 45 min period of ischaemia used here (which in severe brain ischaemia kills \~50% of pericytes: [@bib16]) because, if they did, then adenosine applied around the time of reperfusion would not be able to reduce the amount of capillary constriction and block occurring. However, adenosine only reduces the number of blocked capillaries by 25% ([Figure 3J](#fig3){ref-type="fig"}) and conceivably it would produce a greater restoration of flow if pericyte death were prevented.

It should be recognised that, as with all studies evoking ischaemia by transiently occluding a coronary artery in rodents, our work is only a partial simulation of human cardiac ischaemia. Typically, human myocardial infarct involves the slow build up of a plaque on an artery, which becomes occluded by a thrombus after plaque rupture occurs. This is followed by mechanical removal of the clot (which may compound microvascular obstruction by embolising plaque and thrombus material), leaving an activated oedematous endothelium across which neutrophils invade the tissue ([@bib38]; [@bib39]). Nevertheless, at short times after ischaemia, we expect the constriction that we observe of downstream capillary pericytes to occur also in human cardiac tissue, prolonging the period of ischaemia.

Previously, a combination of myocyte swelling, endothelial cell blebbing and leukocyte plugging have been proposed to block capillaries in ischaemia ([@bib40]). Our demonstration that ischaemia selectively reduces capillary diameter near pericytes suggests that, at least at early times, the majority of capillary blockages in fact occur near pericytes that have constricted the capillaries. These data imply that pericytes are a novel drug target for treating the coronary no-reflow that often occurs after primary percutaneous coronary intervention. It would be interesting to test whether deletion of pericyte-capillary interactions mediated by the angiopoietin/TIE and PDGF/PDGFRβ pathways ([@bib59]) affect the contractile properties of pericytes and their response to ischaemia. We used adenosine to relax pericytes (an effect verified from measurements of capillary diameter at pericyte locations in [Figure 3I--J](#fig3){ref-type="fig"}), but it may also act on arteriolar smooth muscle and lower blood pressure. To reduce no-reflow therapeutically by preventing pericyte constriction of coronary capillaries, it will be necessary to develop agents that act selectively on pericytes. Encouragingly, in the brain it has been shown that signalling pathways regulating pericyte constriction can differ from those regulating arteriole smooth muscle ([@bib33]). Our data also raise the possibility that other organs susceptible to ischaemic no-reflow pathology, such as the kidneys, muscle and skin, may also be damaged by a pericyte-mediated mechanism. Finally, given the proximity of cardiac pericytes to sympathetic terminals ([Figure 1H--J](#fig1){ref-type="fig"}), noradrenaline release may also regulate coronary blood flow at the capillary level in physiological conditions.

Materials and methods {#s4}
=====================

  Reagent type (species) or resource                          Designation                                          Source or reference                                           Identifiers   Additional information
  ----------------------------------------------------------- ---------------------------------------------------- ------------------------------------------------------------- ------------- --------------------------
  *Rattus norvegicus* (Sprague Dawley, male)                  Rat                                                  UCL Biological Services                                                     
  genetic reagent (*Mus musculus/spretus*, male and female)   NG2-DsRed mice                                       doi: 10.1242/dev.004895                                       JAX 008241    
  antibody                                                    anti-NG2 (rabbit polyclonal)                         Merck Millipore                                               AB5320        (1:200)
  antibody                                                    anti-NG2 (mouse monoclonal)                          AbCam                                                         ab50009       (1:200)
  antibody                                                    anti-PDGF receptor beta (rabbit polyclonal)          Santa Cruz Biotechnology                                      sc-432        (1:200)
  antibody                                                    anti-tyrosine hydroxylase (sheep polyclonal)         Merck Millipore                                               AB1542        (1:500)
  antibody                                                    anti-alpha smooth muscle actin (rabbit polyclonal)   AbCam                                                         ab5694        (1:100)
  antibody                                                    anti-beta actin (mouse monoclonal)                   Abbiotec                                                      251815        (1:100)
  antibody                                                    anti-gamma actin (mouse monoclonal)                  AbCam                                                         ab123034      (1:100)
  antibody                                                    anti-glycophorin A (mouse monoclonal)                AbCam                                                         ab9520        (1:2000)
  antibody                                                    anti-neutrophil elastase (goat monoclonal)           Santa Cruz                                                    sc9521        (1:50)
  antibody                                                    anti-ICAM1 (mouse monoclonal)                        AbCam                                                         Ab171123      (1:100)
  antibody                                                    Alexa Fluor 405 goat anti-rabbit (polyclonal)        Life Technologies                                             A31556        (1:500)
  antibody                                                    Alexa Fluor 555 donkey anti-rabbit (polyclonal)      Life Technologies                                             A31572        (1:500)
  antibody                                                    Alexa Fluor 555 donkey anti-mouse (polyclonal)       Life Technologies                                             A31570        (1:500)
  chemical compound                                           isolectin B~4~ - Alexa Fluor 647                     Molecular Probes                                              I32450        (1:200)
  chemical compound                                           isolectin B~4~ - FITC                                Sigma-Aldrich                                                 L2895         (1:200)
  chemical compound                                           adenosine                                            Sigma-Aldrich                                                 A9251         
  chemical compound                                           gelatin                                              Sigma-Aldrich                                                 G2625         5% in PBS
  chemical compound                                           FITC-albumin                                         Sigma-Aldrich                                                 A9771         1:200 in 5% gelatin
  chemical compound                                           DAPI                                                 Molecular Probes                                              D1306         
  chemical compound                                           terazosin                                            Sigma                                                         T4680         
  software                                                    *Spike2*                                             [www.ced.co.uk](http://www.ced.co.uk)                                       in vivo data acquisition
  software                                                    ImageJ                                               <https://imagej.nih.gov/ij/>                                                image analysis
  software                                                    OriginPro                                            [www.originlab.com/Origin](http://www.originlab.com/Origin)                 statistical analysis

Pericyte anatomy {#s4-1}
----------------

Adult Sprague-Dawley rats or, to illustrate morphology, NG2-DsRed mice ([@bib58]) expressing the fluorescent protein DsRed in pericytes, of either sex, were sacrificed by UK government approved methods (anaesthetic overdose with 5% isoflurane in 100% O~2~, followed by cervical dislocation). Hearts were harvested and immersion-fixed in ice cold 4% paraformaldehyde (PFA). Immunohistochemistry was performed on 150 μm thick transverse ventricular slices.

Immunohistochemistry {#s4-2}
--------------------

Pericytes were labelled by expression of DsRed under control of the NG2 promoter (in mice), or with anti-NG2 (Merck Millipore AB5320 1:200 or AbCam ab50009 1:200) or anti-PDGFRβ (Santa Cruz Biotechnology sc-432 1:200) antibodies (in rats), and the capillary basement membrane was labelled with isolectin B~4~ congugated to Alexa Fluor 647 (Molecular Probes, I32450) or FITC (Sigma-Aldrich, UK, L2895) as described ([@bib32]). Pericyte association with sympathetic terminals was imaged using antibody to tyrosine hydroxylase (Merck Millipore AB1542 1:500). Z-stacks for cell counting were acquired using laser-scanning confocal microscopy (Zeiss LSM 700). Pericyte intersoma distance was calculated between pairs of pericytes on capillaries within the same imaging plane. Antibodies to α-SMA, β-actin and γ~1~ actin were AbCam ab5694 (1:100), Abbiotec 251815 (1:100) and AbCam ab123034 (1:100). Red blood cells were labelled with antibody to glycophorin A (AbCam ab9520, 1:2000). Neutrophils were labelled with antibodies to neutrophil elastase (Santa Cruz, sc9521 (M-18), 1:50) or ICAM1 (Abcam, Ab171123, 1:100).

Animal preparation for ischaemia experiments {#s4-3}
--------------------------------------------

Adult male Sprague-Dawley rats (200--220 g) were anaesthetized with pentobarbital sodium (induction 60 mg/kg i.p.; maintenance 10--15 mg/kg/h i.v.). The right carotid artery and jugular vein were cannulated for measurement of arterial blood pressure and administration of anaesthetic and tested substances, respectively. Stable levels of blood pressure and heart rate were maintained, and adequate anaesthesia was monitored by the absence of a withdrawal response to a paw pinch. The trachea was cannulated, and the animal was mechanically ventilated with room air using a positive pressure ventilator (tidal volume of 1 ml/100 g of body weight, ventilator frequency ∼60 strokes min^−1^). *P*O~2~, *P*CO~2~ and pH of the arterial blood were measured regularly and, if required, ventilation was adjusted to maintain values within their physiological ranges. Arterial BP and a standard lead II ECG were recorded using a Power1401 interface and *Spike2* software (Cambridge Electronic Design). Body temperature was maintained at 37.0 ± 0.5°C with a servo-controlled heating pad.

Myocardial ischaemia and reperfusion {#s4-4}
------------------------------------

The heart was exposed via a left thoracotomy and a 4--0 prolene suture was passed around the left anterior descending (LAD) coronary artery to induce a temporary occlusion as previously described ([@bib30]; [@bib2]). The animals were subjected to 45 min of LAD artery ligation, followed by 15 min of reperfusion. Successful LAD occlusion was confirmed by paling of the myocardial tissue distal to the suture, elevation of the ST-segment in the ECG, and an immediate 15--30 mm Hg fall in the ABP. In rats LAD occlusion deprives of blood not only the anterior wall of the left ventricle but also part of the right ventricle ([@bib48]), as seen in [Figure 2](#fig2){ref-type="fig"}. Control (sham operated) animals underwent the same procedures, except that after the suture was passed around the LAD coronary artery it was not drawn tight to occlude the vessel. Ischaemia and sham animals were alternately interleaved.

In some experiments *i.v.* adenosine (Sigma-Aldrich, St. Louis, Missouri) was administered (with the aim of relaxing pericytes), starting 5 min before the end of ischaemia and continuing until 10 min of reperfusion (0.5 mg/kg/min in saline, 2 mg/ml, cumulative dose 7.5 mg/kg), which lowered the blood pressure reversibly by 10--15 mm Hg (10%). Control animals received vehicle (saline) infusion. For comparison, in cats 0.5 mg/kg/min is approximately the upper limit ([@bib44]) for restricting the adenosine-induced fall of blood pressure to less than 10%, in rats a cumulative dose of 3 mg/kg reduced infarct size by 31% ([@bib51]), and in humans infusing 0.07 mg/kg/min for 3 hr during reperfusion (a cumulative dose of 12.6 mg/kg) reduced infarct size by 57% in the AMISTAD-II trial ([@bib47]), although the REFLO-STEMI trial found no beneficial effect of adenosine ([@bib35]).

Animal perfusion and tissue preparation for imaging {#s4-5}
---------------------------------------------------

At the end of ischaemia/reperfusion animals were overdosed with pentobarbital sodium and transcardially perfused with saline (200 ml) followed by 4% paraformaldehyde (PFA, 200 ml) for fixation and then 20 ml of 5% gelatin (Sigma-Aldrich, G2625) solution containing FITC-albumin conjugate (Sigma-Aldrich, A9771) to enable visualization of the perfused coronary microvasculature. The hearts were then fixed overnight in 4% PFA, and 150 µm transverse sections made for immunofluorescence staining. Pericytes were labelled with anti-NG2 antibodies (Merck Millipore) and the capillary basement membrane and pericytes were labelled ([@bib32]) with isolectin B~4~-Alexa Fluor 647 (Molecular Probes, I32450).

The capillary diameters we measure with this protocol are not affected by vessels being compressed by myocyte contraction. The initial perfusion with calcium-free saline stops the heart in diastole. Evidence that the heart is indeed arrested in diastole is provided by the large volume visible within the left ventricle ([Figure 2A,C](#fig2){ref-type="fig"}), which matches that seen during diastole in magnetic resonance images of rat heart, which also show that the volume during systole is far smaller (see Figure 2B of [@bib6]). Indeed, it is clear that the observation of occluded capillaries after ischaemia does not reflect compression by arrest in systole, because essentially no capillary block was observed in control hearts that were not made ischaemic (only 3% of capillaries were blocked, compared to 40% after ischaemia: see [Figure 2D](#fig2){ref-type="fig"}). Another demonstration that the observation of occluded capillaries does not reflect compression by arrest in systole is provided by the fact that capillary occlusion ([Figure 2D](#fig2){ref-type="fig"}) and reduction of FITC-albumin labelling ([Figure 2B](#fig2){ref-type="fig"}) were only seen on the side of the heart where the blood supply was transiently interrupted, and not on the normally perfused side of the heart, and were specifically associated with pericytes ([Figure 3H](#fig3){ref-type="fig"}). Furthermore, our mean capillary diameter in control hearts (5.38 ± 0.28 microns, see [Figure 3J](#fig3){ref-type="fig"}) is similar to that estimated for capillaries in diastole in rat hearts (measured in relaxed hearts as 5.3 microns with a suggested correction to 5 microns: see [@bib18]) and is greater than the diameter estimated for systole (\~4 microns: [@bib18]).

Imaging of vessels after ischaemia experiments {#s4-6}
----------------------------------------------

Image z-stacks of overall left ventricular myocardial blood volume, the perfusion of capillaries in the area at risk, and individual vessel blockages, were acquired using laser scanning confocal microscopy (Zeiss LSM 700), and analysed using ImageJ software (NIH, Bethesda, MD, USA). To quantify blood volume across the left ventricular myocardium,\~30 low power z-stacks were taken of an entire transverse section of each heart (using a 5X air objective), maximum intensity projected, and stitched together using the MosaicJ plugin ([@bib54]) of ImageJ (n = 6 hearts for ischaemia, n = 8 for ischaemia +adenosine, n = 5 for control). Usually some FITC-albumin labelled blood remained within the lumen of the ventricles (although this blood often became detached during tissue processing). For ease of interpretation of the images in [Figure 2](#fig2){ref-type="fig"}, this labelling (and also the area outside the imaged heart) was digitally recoloured black using Photoshop. All quantification of the FITC labelling was carried out on the unedited images.

For quantification of the percentage of capillaries that were perfused, three randomly selected regions of the anterior left ventricle wall were imaged in both ischaemia and sham animals, as this region of myocardium consistently included the ischaemic area (which showed visible pallor and oedema of the myocardium). The person quantifying the images was blinded to the condition that the heart was exposed to. 75 stacks (160 μm square, and 20 μm deep) in 12 different animals were taken (ischaemia n = 4, ischaemia +adenosine n = 5, control n = 3). Blockages of flow in the ischaemic area at risk were identified by abrupt terminations in FITC-IB~4~ signal. For ischaemia 42 blockages were imaged; for ischaemia +adenosine 14 blockages were imaged. Clots (or red blood cell rouleaux) were very rarely observed.

Image analysis {#s4-7}
--------------

For low power blood volume analysis, 12 regions of interest (ROI) were drawn clockwise around the left ventricle (when looked at from above) from the mid-point of the septum (as in [Figure 2A](#fig2){ref-type="fig"}), and the mean intensity of FITC-albumin signal was recorded for each ROI, and normalised to the highest intensity measured in any ROI. These data were averaged over hearts and renormalized so that the mean value in positions 1--3 of [Figure 2C](#fig2){ref-type="fig"} was 1. This signal is assumed to be proportional to the volume of blood perfusing the myocardium. To compare perfusion in the ischaemic zone, we averaged the plotted values over ROIs 7--10 for each heart in the different conditions, and compared the mean values averaged over all the hearts studied in each condition.

To quantify the percentage of perfused capillaries, we counted the number of filled and unfilled vessels crossing a line drawn through the centre of each image perpendicular to the main capillary axis.

For blockages in flow, we measured the distance along the capillary from the termination of the FITC-albumin signal to the mid-point of the nearest visible pericyte soma on the same capillary. The cumulative probability distribution of the blockage-to-nearest-soma distance (over all blocked capillaries) was compared with the distribution predicted for random placement of a blockage on each blocked capillary. If pericytes were a uniform 60 μm distance apart ([Figure 1F](#fig1){ref-type="fig"}) along unbranched capillaries, then the latter cumulative probability distribution for the blockage-to-nearest-soma distance would increase linearly with distance, to reach a value of 1 at a distance of 30 μm (half the distance between two pericytes). In practice, pericytes vary in their separation, vessels branch and, because it was necessary to image at high magnification to reliably locate blockage sites, sometimes the blocked vessel passes out of the image before one of the pericytes adjacent to the block is reached (making it uncertain whether all positions on the imaged capillary are in fact closest to the imaged pericyte, rather than one outside of the image). We calculated the expected cumulative probability distribution of the distance from imaged pericytes to a randomly positioned vessel blockage as follows. For each blocked capillary the probability, p(x).dx, of a location on the capillary (and hence a potential blockage location) existing between distances x and x + dx from the pericyte soma (with x ≥ 0) was calculated as a function of distance from the soma (see [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). For example, for a capillary of length L in the image, with a single pericyte soma located a distance A from one end, the probability is

p(x).dx=2.dx/L for x \< A,

p(x).dx=dx/L for A \< x \< L-A,

and p(x).dx=0 for x \> L A,

with the total probability (integrated along the capillary length) summing to 1. For more complicated geometries (e.g. two pericytes on the blocked capillary, or branching capillaries) the same approach was used to calculate p(x), taking into account all possible positions on the capillaries. The resulting probability distribution was then averaged over all 42 images used for [Figure 3H](#fig3){ref-type="fig"}. To generate a predicted cumulative probability distribution with the same resolution as that obtained for the experimentally observed blockages, this smooth distribution was then sampled at 42 equi-probability points as shown in [Figure 3H](#fig3){ref-type="fig"}.The resulting distribution shows a deviation from a linear increase to a value of 1, at 30 μm distance, because of the factors mentioned above.

Statistics {#s4-8}
----------

Statistical analysis employed OriginPro. Data normality was assessed with Shapiro-Wilk tests. Comparisons of normally distributed data were made using 2-tailed Student's t-tests. Equality of variance was assessed with an F test, and heteroscedastic t-tests were used if needed. Data that were not normally distributed were analysed with Mann-Whitney tests. P values were corrected for multiple comparisons using a procedure equivalent to the Holm-Bonferroni method (for N comparisons, the most significant p value is multiplied by N, the 2nd most significant by N-1, the 3rd most significant by N-2, etc.; corrected p values are significant if they are less than 0.05). Cumulative probability distributions were compared using the Kolmogorov-Smirnov test. An estimate of the sample size needed for a typical experiment is as follows: For a control response of 100%, a response standard deviation of 25%, a response after a manipulation (ischaemia or adenosine) of 50% (50% inhibition), a power of 80% and p\<0.05, 6 samples are needed (<http://www.biomath.info/power/ttest.htm>) in each of the control and manipulation groups. The exact numbers depend on the effect size for the manipulation and the standard error of the data.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Capillary pericytes mediate coronary no-reflow after myocardial ischaemia\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, one of whom, Reinhard Fässler, has agreed to reveal his identity. The evaluation has been overseen by Fiona Watt as the Senior Editor and Reviewing Editor.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

O\'Farrell et al. have examined a possible role for microvascular pericytes in post-cardiac ischemia lack of capillary reperfusion, or \"no-reflow\". The question is important and of high medical significance. The report is well written and, overall, well illustrated. The first part of the work is a description of vascular cell types in the rat myocardium after lectin (IB4) binding and surface marker visualisation, by IHC or in transgenic reporter mice.

Next, rat heart ischemia was created by coronary artery ligation, and no-reflow documented in the microvasculature after systemic injection of FITC-albumin. Precise statistical comparison between sites of blood flow interruption and pericyte position, correlated with reduction in vessel diameter, led the authors to conclude that lack of capillary reperfusion was a consequence of pericyte constriction. In agreement with this, administration of adenosine, a pericyte relaxant, reduced the number of blocked capillaries and, consequently, improved reperfusion. This extends to the cardiac microvasculature observations made previously by the same group on brain blood vessels and may indicate cardiac pericytes as therapeutic target cells in cardiac ischemia.

Essential revisions

1\) In the reported experiments, capillary diameter reduction resulting from pericyte constriction is of the order of 37%, which is not necessarily sufficient to interrupt the blood flow (or, at least, the plasma flow) unless, as suggested by the authors, blood cells cannot crawl through the constriction and eventually completely clog the conduit. This latter point should be investigated by immunohistochemical detection of glycophorin A and CD45, for instance, on sections such as those shown in [Figure 3](#fig3){ref-type="fig"}. In addition, there is no clear indication if the heart was perfused with a solution that allows stopping the heart in diastole. This condition is essential to avoid the possibility that some vascular areas are occluded by contraction.

2\) It is possible that the differences in cell death of pericytes in the present paper and the earlier Nature paper would disappear if identical occlusion and reperfusion times had been used. The authors need to examine this possibility experimentally.

3\) Not all pericytes express α-SMA, although the distribution of contractile and non-contractile pericytes among venules, arterioles and capillaries and in different organs remains to be precisely described. Immunohistochemical detection of α-SMA expression by pericytes adjacent to capillary blockage spots would add strength to the paper, even more so if more distant pericytes are found to be α-SMA negative. In addition, the definition of pericytes requires additional staining. How do the authors exclude the possibility that some NG2-cells are vascular muscle cells?

4\) Adenosine is a widely used vasodilator, acting via e.g. A2 receptors to dilate smooth muscle cells. If A2 receptors are expressed on pericytes, they would dilate, too. The primary effect of adenosine is exerted on smooth muscle cells both preclinically and in preconditioning scenarios such as reactive hyperemia. The claim that adenosine works predominantly on pericytes needs more convincing evidence. In addition, the mechanism of pericyte contraction is hypothetical. The authors should test whether neuroadrenergic blockade reverses the phenomenon.

Other comments

1\) The paper contains nice images showing pericytes encircling capillary vessels. Less expected is the observation that some vessels are devoid of pericyte coverage ([Figure 1E](#fig1){ref-type="fig"}). Could these be very small, or tangentially sectioned venules (hence associated with NG2-negative pericytes)? This point deserves comments in the discussion.

2\) Important control experiments, in which pericyte functions are abrogated (e.g. via Angiopoietin-2) are missing.

3\) The authors do not provide adequate context for their observations in terms of the pathophysiology of no-reflow, which requires a plaque, an occluding thrombus, a mechanical removal of the clot by balloon inflation and an activated, edematous microvascular endothelium. In addition, the roles of invading neutrophils and platelets are not discussed. The study is conducted in mice and the limitation of the model should be considered, as the human vasculature is different from rodents in several important respects.

10.7554/eLife.29280.010

Author response

> Essential revisions
>
> 1\) In the reported experiments, capillary diameter reduction resulting from pericyte constriction is of the order of 37%, which is not necessarily sufficient to interrupt the blood flow (or, at least, the plasma flow) unless, as suggested by the authors, blood cells cannot crawl through the constriction and eventually completely clog the conduit. This latter point should be investigated by immunohistochemical detection of glycophorin A and CD45, for instance, on sections such as those shown in [Figure 3](#fig3){ref-type="fig"}.

As the referees note, ischaemia-evoked pericyte constriction reduces the capillary diameter by 37% to 3.4 microns at pericyte locations ([Figure 3J](#fig3){ref-type="fig"}). However, this value is for *all* pericyte somata, not just those that evoked capillary block (and furthermore the block often did not occur exactly at the pericyte soma), so this value is not the diameter associated precisely with the location of blockages. We have now explained more clearly in the legend to [Figure 3J](#fig3){ref-type="fig"} that it is the mean diameter at all pericyte somata that is plotted, and mentioned that if only pericytes associated with blockages are selected then the diameter is less (3.19 ± 0.24 μm, n=30). Nevertheless, even this reduction in diameter is apparently not sufficient to completely occlude the vessel, which raises the referee's question of whether cells get stuck at the regions of reduced diameter.

As is now explained in subsection "Pericytes constrict capillaries after ischaemia", since leukocytes are both larger than erythrocytes (8.5 microns compared with 7.2 microns in diameter: Komatsu et al., 1990, Microvasc Res 40, 1) and less deformable than erythrocytes (Schmid-Schonbein et al., 1981, Biophys J 35, 243; Downey et al., 1985, J Appl Physiol 69, 1767; Doerschuk et al., 1993, J Appl Physiol 74, 3040), we expected that leukocytes rather than red blood cells would get stuck at capillary regions constricted by pericytes. As suggested by the referee, we attempted to demonstrate leukocyte or red blood cell trapping at sites of capillary constriction by pericytes.

Firstly, we examined labelling with antibody to neutrophil elastase or ICAM-1 (since granulocytes may block coronary capillaries and cause no-reflow: Engler et al., (1983, 1986), but see Habazettl et al., (1999, references in our paper). Surprisingly, although we could detect leukocytes outside vessels ([Figure 3K](#fig3){ref-type="fig"}; usually post-capillary venules but also some capillaries), we observed none in the lumen at 46 sites of capillary block. On the other hand, when we labelled red blood cells with antibody to glycophorin A, as suggested, we did observe that some blockages had red blood cells stuck in them, but this was not a universal feature of blockages (only 18% of 44 blockages were occluded by red blood cells) and the presence of a red blood cell at a constriction did not guarantee a blockage of blood flow.

We have now described these data in subsection "Pericytes constrict capillaries after ischaemia"2, as follows:

"Surprisingly, labelling with antibody to neutrophil elastase or ICAM-1 revealed no leukocytes lodged at 46 blockage sites examined (although, as a positive control, they were seen outside vessels, [Figure 3K](#fig3){ref-type="fig"}, usually post-capillary venules). Similarly, labelling for the erythrocyte protein glycophorin A revealed red blood cells ([Figure 3L](#fig3){ref-type="fig"}) associated with only a small percentage of blockage sites (18% of 44 blockages), and even where red blood cells were trapped at capillary constrictions it did not always lead to a block of blood flow (as shown by FITC-albumin passing the red blood cells)".

We have also added, as [Figure 3K and 3L,](#fig3){ref-type="fig"}a picture of red blood cells occluding a capillary at a pericyte location and an image of a blockage lacking neutrophil elastase labelling but showing a neutrophil outside a capillary. Furthermore, in the Discussion section, we have now speculated that:

"The fact that we observed few cells in the capillary lumen at blockages may result from their displacement during the perfusion with FITC-albumin in gelatin, or may alternatively reflect capillary block occurring when constriction brings together the layers of glycocalyx (Secomb et al., 1998) on opposite sides of the capillary.".

> In addition, there is no clear indication if the heart was perfused with a solution that allows stopping the heart in diastole. This condition is essential to avoid the possibility that some vascular areas are occluded by contraction.

The referees are referring to the fact that, on each cardiac cycle, blood flow through the cardiac capillaries is prevented in systole because of the contraction of the myocardium. There are 5 lines of evidence implying that this does not affect our assessment of capillary block by pericyte constriction, as follows.

i\) First, the heart is stopped in diastole by the perfusion of calcium-free saline, before perfusion of the green (FITC-albumin) label used to define perfused and non-perfused vessels.

ii\) Evidence that the heart is indeed arrested in diastole is provided by the large volume visible within the left ventricle ([Figure 2A, B](#fig2){ref-type="fig"}), which matches that seen during diastole in magnetic resonance images of rat heart, which also show that the volume during systole is far smaller (see [Figure 2B](#fig2){ref-type="fig"} of Crowley et al., 1997, Exp Physiol 82, 887).

iii\) It is clear that the observation of occluded capillaries after ischaemia does not reflect compression by arrest in systole, because essentially no capillary block was observed in control hearts that were not made ischaemic (only 3% of capillaries were blocked, compared to 40% after ischaemia: see [Figure 2D](#fig2){ref-type="fig"}).

iv\) Another demonstration that the observation of occluded capillaries does not reflect compression by arrest in systole is provided by the fact that capillary occlusion ([Figure 2D](#fig2){ref-type="fig"}) and reduction of FITC-albumin labelling ([Figure 2C](#fig2){ref-type="fig"}) were only seen on the side of the heart where the blood supply was transiently interrupted, and not on the normally perfused side of the heart, and were specifically associated with pericytes ([Figure 3H](#fig3){ref-type="fig"}).

v\) Finally, our mean capillary diameter in control hearts (5.38[+]{.ul}0.28 microns, see [Figure 3J](#fig3){ref-type="fig"}) is similar to that estimated for capillaries in diastole in rat hearts (measured in relaxed hearts as 5.3 microns with a suggested correction to 5 microns: see Henquell et al., 1976, Microvasc Res, 12, 259) and is greater than the diameter estimated for systole (\~4 microns: Henquell et al., 1976, Microvasc Res, 12, 259).

We have now explained all this in the Materials and methods section.

> 2\) It is possible that the differences in cell death of pericytes in the present paper and the earlier Nature paper would disappear if identical occlusion and reperfusion times had been used. The authors need to examine this possibility experimentally.

In fact, we did not investigate pericyte death in the current paper, but merely mentioned that the significant reversal of part of the 37% post-ischaemic decrease in capillary diameter at pericyte locations ([Figure 3J](#fig3){ref-type="fig"}) seen on adding adenosine after the ischaemia indicates that not all the pericytes can be dead. The duration of ischaemia we use in these experiments (45 mins) is in fact included in the chemical ischaemia protocol that we used for brain pericytes (Figure 4C of Hall et al., 2014, Nature 508, 55), where it led to the death of approximately 50% of pericytes (on the y axis of that figure, 3.3 dead pericytes/100 microns is equivalent to 100% death, which took just over an hour). The fact that, in the current work, adenosine only allowed partial (and not complete) recovery of the decrease in flow would be consistent with some pericytes having died in rigor at the end of the ischaemia (in which case the percentage dead could be similar to that induced by chemical ischaemia in brain slices).

We have now discussed all this in the Discussion section of the paper and stated that adenosine might produce a greater restoration of flow if pericyte death were prevented.

> 3\) Not all pericytes express α-SMA, although the distribution of contractile and non-contractile pericytes among venules, arterioles and capillaries and in different organs remains to be precisely described. Immunohistochemical detection of α-SMA expression by pericytes adjacent to capillary blockage spots would add strength to the paper, even more so if more distant pericytes are found to be α-SMA negative.

The heterogeneity of a-SMA expression that the referee mentions has led to suggestions that, for the CNS, it might be γ-actin rather than a-SMA that mediates contraction. We have now carried out further experiments to assess which actin isoform might mediate the contraction of pericyte processes that underlie capillary constriction after cardiac ischaemia. First, we examined the fraction of pericytes that express different smooth muscle actin isoforms. The results are shown in [Figure 1K-N](#fig1){ref-type="fig"} and described in subsection "Pericytes associate with capillaries and sympathetic axons, and express actin",as follows:

"Pericytes are conventionally assumed to constrict capillaries using α-smooth muscle actin (α-SMA: Joyce et al., 1985; Skalli et al., 1989), but variability in the labelling observed for α-SMA and data showing expression of other actin isoforms in pericytes has led to a suggestion, for CNS pericytes, that γ-actin might instead be the relevant actin isoform (DeNofrio et al., 1989; Grant et al., 2017). We therefore examined antibody labelling for α-SMA, β-actin and γ-actin ([Figure 1K-M](#fig1){ref-type="fig"}). α-SMA labelling occurred in 36.4 ± 6.7% of 57 pericytes ([Figure 1N](#fig1){ref-type="fig"}), and was rarer than labelling for β-actin (62.3 ± 2.8% of 30 pericytes) or γ-actin (76.0 ± 3.4% of 47 pericytes). α-SMA-expressing pericytes were most commonly observed in capillaries closer to the arteriole end of the capillary bed, while β- and γ-actin were seen in pericytes across the capillary bed."

We find that after ischaemia the capillary diameter at pericyte somata is reduced more near blockages (reduced to 3.19 ± 0.24 μm as mentioned above) than at non-block locations (3.64 ± 0.23 μm), but even the latter diameter is reduced from that in control conditions (5.38 ± 0.28 μm, significantly different, p=1.56x10^-5^). This implies that it is not the case that only a small fraction of pericytes -- for example those that express α-SMA -- constrict capillaries in ischaemia. Instead they may all constrict, with the blockages occurring at the sites of greatest constriction. Examining actin isoform labelling of pericytes located at blockages, we obtained the following results, which are now described in subsection "Pericytes constrict capillaries after ischaemia***"***and shown in [Figure 3M](#fig3){ref-type="fig"}:

"Pericytes near blockage sites were tested for labelling of the different actin isoforms mentioned above. All 4 such pericytes tested for α-SMA labelling exhibited labelling ([Figure 3M](#fig3){ref-type="fig"}), as did 5 out of 6 tested for β-actin, and all 6 tested for γ-actin. Since only a small fraction of pericytes may need to constrict a capillary to abolish its blood flow, further work is needed to determine which is the main actin isoform responsible for the ischaemia-evoked contraction of pericyte processes and reduction of blood flow."

> In addition, the definition of pericytes requires additional staining. How do the authors exclude the possibility that some NG2-cells are vascular muscle cells?

The main markers used to define pericytes in most studies are NG2 and PDGFRβ. As requested, we have now carried out further labelling, and added images to [Figure 1C](#fig1){ref-type="fig"} showing that the cells we are studying express both NG2 and PDGFRβ. Furthermore, we have now quantified overlap of the expression of these markers in left ventricular cardiac pericytes in adult NG2-DsRed mice. In the left ventricle, 99.2 ± 0.2% of NG2-expressing pericytes also expressed PDGFRβ (2852 of 2874 cells analysed in 36 z-stacks from 4 mice). Furthermore, 93.6 ± 1.0% of PDGFRβ-expressing pericytes also expressed NG2 (2852 of 3047 cells analysed in 36 z-stacks from 4 mice). This value is significantly different to 100% (p=2.3x10^-7^), suggesting that there may be a small population (6.4%) of PDGFRβ-expressing pericytes not expressing NG2.

These results have now been described in subsection "Pericytes associate with capillaries and sympathetic axons, and express actin" and the legend to [Figure 1D](#fig1){ref-type="fig"}, and shown in [Figure 1C-D](#fig1){ref-type="fig"}.

The referee questions the distinction between pericytes and vascular smooth muscle cells (SMCs). A similar question has recently arisen for pericytes in the CNS, and been assessed in depth (Attwell et al., 2016, JCBFM 36, 451) in the light of the historical definition of pericytes. In brief, the distinction between pericytes and SMCs is an anatomical one. SMCs consist of immediately adjacent band-like cells running around arterioles, while pericytes have spatially-separated somata (located either with a bump-on-a-log appearance on the straight parts of capillaries, or at capillary branch points) and are found all along the capillary bed. It is important to note that pericytes may differ in the morphology of their processes (and possibly also in the proteins they express) at different positions along the capillary bed but, nevertheless, the historical definition of pericytes encompassess all of these forms of the cells (Attwell et al., 2016, JCBFM 36, 451). The anatomical definition of pericytes has now been stated on page 4, para 1, of the manuscript.

> 4\) Adenosine is a widely used vasodilator, acting via e.g. A2 receptors to dilate smooth muscle cells. If A2 receptors are expressed on pericytes, they would dilate, too. The primary effect of adenosine is exerted on smooth muscle cells both preclinically and in preconditioning scenarios such as reactive hyperemia. The claim that adenosine works predominantly on pericytes needs more convincing evidence.

We are certainly not claiming that adenosine acts only on pericytes, and it is indeed likely to also relax arteriolar smooth muscle cells (an effect we now mention in subsection "Adenosine reduces pericyte constriction and no-reflow"). However, we are claiming that adenosine can reduce no-reflow after cardiac ischaemia by relaxing pericytes. Indeed, we already provide direct evidence in the paper for adenosine relaxing pericytes. In [Figure 3J](#fig3){ref-type="fig"} we show that i) after ischaemia, the capillary diameter at pericyte locations is reduced by 37%; and ii) after ischaemia plus adenosine on reperfusion, the capillary diameter is reduced by only 23%.

Thus, adenosine has dilated the pericytes.

Evidence that this is not a general effect on the capillaries, unrelated to the pericytes, is provided in [Figure 3I](#fig3){ref-type="fig"}, where we show that the effects of ischaemia and of adenosine are specific to the location of the pericyte soma, and are not seen 10 microns away.

We have now stressed in the Abstract that the capillary dilation produced by adenosine occurs specifically at pericytes. We have also discussed this in subsection "Adenosine reduces pericyte constriction and no-reflow" --, where we state:

"This increase of flow could reflect adenosine acting both on arteriolar smooth muscle and on pericytes. However, adenosine also reduced by one quarter the percentage of capillaries that were blocked after reperfusion, from \~40% to \~30% (p=0.007, [Figure 2D](#fig2){ref-type="fig"}). \[...\] Since the capillary blockages induced by ischaemia in the absence of adenosine are disproportionately associated with pericytes, and since the adenosine was only applied around the period of reperfusion, these data suggest that, at least in part, adenosine reduces no-reflow by reversing the constriction of pericytes that ischaemia induces. To test this hypothesis, we compared the diameter of capillaries at pericyte somata with the diameter 10 μm upstream of the soma and found that adenosine significantly (p=0.0045) reduced the constriction evoked by ischaemia at pericyte somata ([Figure 3I](#fig3){ref-type="fig"}), implying a specific effect on pericytes (rather than a general capillary dilation produced by upstream arteriole dilation). The absolute capillary diameter at pericyte somata after ischaemia was increased by 21% using adenosine (p=0.025, [Figure 3J](#fig3){ref-type="fig"}). Thus, adenosine decreases no-reflow by relaxing pericytes."

> In addition, the mechanism of pericyte contraction is hypothetical. The authors should test whether neuroadrenergic blockade reverses the phenomenon.

We expect that, as for brain pericytes (Hall et al., 2014), the loss of energy supply in ischaemia will lead to a rise of \[Ca^2+^\]~i~ which evokes contraction, as stated at the start of the Discussion. However, noradrenaline is released in ischaemia (as we already stated in the Discussion) so, as requested, we assessed the effect of blocking vasoconstrictive α~1~ receptors with terazosin. This had no effect on the percentage of capillaries remaining blocked after ischaemia. These data are described insubsection "Pericytes constrict capillaries after ischaemia" --, where we state:

"We found no effect of injecting terazosin (0.5 mg/kg i.v., 5 mins before occluding the LAD artery, which produced a 20-33 mm Hg decrease of blood pressure), with 48.8 ± 3.7% blocked in the presence of terazosin (in 13 images covering 383 capillaries in 2 hearts; not significantly different from the 44.7 ± 4.9% seen for 14 images covering 366 capillaries in 2 hearts in interleaved experiments without terazosin, p=0.52)."

> Other comments
>
> 1\) The paper contains nice images showing pericytes encircling capillary vessels. Less expected is the observation that some vessels are devoid of pericyte coverage ([Figure 1E](#fig1){ref-type="fig"}). Could these be very small, or tangentially sectioned venules (hence associated with NG2-negative pericytes)? This point deserves comments in the discussion.

In general, the cardiac capilaries are fairly uniformly invested with pericytes, as shown in [Figure 1A](#fig1){ref-type="fig"}. It is true that [Figure 1G](#fig1){ref-type="fig"} (previously [Figure 1E](#fig1){ref-type="fig"}) shows a few vessels with stretches of 40 microns that appear to have no pericytes (in fact there are some pericyte processes present on two of the four vessels that we believe the referee means, but they are labelled too dimly to be visible without over-saturating the representation of the brighter-labelled pericytes in the picture). The vessels shown were completely within the confocal planes imaged, and so do not reflect tangential sectioning of vessels. They are also unlikely to be venules because of their small diameter (\<4 microns for the least labelled vessels in [Figure 1G](#fig1){ref-type="fig"}). However, with a mean distance between pericyte somata of almost 60 microns ([Figure 1F](#fig1){ref-type="fig"}), random variation will result in occasional capillary lengths of 40 microns that lack pericyte somata and processes (indeed we already discussed the effect of this variation in the Image Analysis section of the Materials and methods section). As requested, we have now added a comment on this in subsection "Pericytes associate with capillaries and sympathetic axons, and express actin", where we report the mean distance between pericytes.

> 2\) Important control experiments, in which pericyte functions are abrogated (e.g. via Angiopoietin-2) are missing.

We agree that it would be of interest to investigate whether deletion of signalling via the angiopoietin/TIE and PDGF/PDGFRbeta pathways affect the contractile properties of cardiac pericytes and their response to ischaemia. These pathways have been shown to regulate pericyte adhesion to vessels and capillary permeability, both in the CNS (Gurnik et al., 2016, Acta Neuropathol 131, 753; Part et al., 2016, Nat. Commun. 8, 15296; Daneman et al., 2010, Nature 468, 562; Bell et al., 2010 Neuron 68, 409; Armulik et al., 2010, Nature 468, 557) and in the heart (Ziegler et al., 2013, PMID: 23863629), but it is unknown whether loss or over-expression of this signalling affects expression of contractile proteins by pericytes. We estimate that it would take about 2 years to conduct such a study, given the need to (i) transfer our ischaemia techniques from rat to mouse, (ii) generate colonies of mice with molecules deleted specifically from cardiac pericytes or endothelial cells (global deletion is not sufficient as it modifies peripheral resistance: Ziegler et al., 2013 PMID: 23863629), and (iii) carry out the experiments. We believe these experiments are therefore outside the scope of this study, but we have now added a sentence in the Discussion section suggesting such an approach for the future and citing the Ziegler et al., (2013) paper.

> 3\) The authors do not provide adequate context for their observations in terms of the pathophysiology of no-reflow, which requires a plaque, an occluding thrombus, a mechanical removal of the clot by balloon inflation and an activated, edematous microvascular endothelium. In addition, the roles of invading neutrophils and platelets are not discussed. The study is conducted in mice and the limitation of the model should be considered, as the human vasculature is different from rodents in several important respects.

We have now added a paragraph dealing with this in the Discussion section.

[^1]: These authors contributed equally to this work.
